Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study - Wikidata - wikimedia - TriplyDB

Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study

Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study

http://www.wikidata.org/entity/Q34944648

about

Management of antipsychotic-related weight gain Schizophrenia: a multisystem disease?Unmet needs in the management of schizophrenia An overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologists Evaluation of service users' experiences of participating in an exercise programme at the Western Australian State Forensic Mental Health Services.A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients.The incidence and prevalence of diabetes in patients with serious mental illness in North West Wales: two cohorts, 1875-1924 & 1994-2006 compared.The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Prevalence of metabolic syndrome among patients with schizophrenia in Palestine.Schizophrenia and potentially preventable hospitalizations in the United States: a retrospective cross-sectional study.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.The prevalence of metabolic syndrome amongst patients with severe mental illness in the community in Hong Kong--a cross sectional study.Almost all antipsychotics result in weight gain: a meta-analysis.Cardiovascular morbidity and mortality in bipolar disorder.Metabolic abnormalities among people diagnosed with schizophrenia: a literature review and implications for mental health nurses.Mental illness related disparities in diabetes prevalence, quality of care and outcomes: a population-based longitudinal study Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics--results from a German observational study.Genetic Evaluation of Schizophrenia Using the Illumina HumanExome Chip Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis Diabetes and glucose disturbances in patients with psychosis in Sweden.Beyond the brain: disrupted in schizophrenia 1 regulates pancreatic β-cell function via glycogen synthase kinase-3β.Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis.Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review.Metabolic syndrome in people with schizophrenia: a review.Possible associations between antioxidant enzyme polymorphisms and metabolic abnormalities in patients with schizophrenia.Metabolic syndrome in schizophrenia.Patient Safety Events and Harms During Medical and Surgical Hospitalizations for Persons With Serious Mental Illness.Metabolic profile at first-time schizophrenia diagnosis: a population-based cross-sectional study.Health management of older persons with chronically medicated psychotic disorders: the results of a survey in France.The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes.The interface of physical and mental health.Patient, Provider, and System Factors Contributing to Patient Safety Events During Medical and Surgical Hospitalizations for Persons With Serious Mental Illness.Atypical antipsychotics and effects on feeding: from mice to men.Severity of hypertension predicts the generalized neurocognitive deficit in schizophrenia.Medical comorbidities in patients with serious mental illness: a retrospective study of mental health patients attending an outpatient clinic in Qatar.No association between genetic or epigenetic variation in insulin growth factors and antipsychotic-induced metabolic disturbances in a cross-sectional sample.Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder.Physical health promotion for young people at ultra-high risk for psychosis: An application of the COM-B model and behaviour-change wheel.

P2860

Q24610124-F7014B49-49A0-41C3-8A71-737A3FF55F95 Q24633845-E2E7C10C-F724-419D-9495-C9BE09B56A6B Q26822917-C81FF346-1CB9-4FA4-B714-FE931BBCCF89 Q26859927-4B29A158-7DD0-4114-A47A-DA6C6BF8AA01 Q30416019-98E809A8-6658-47ED-8F9A-11F4D12CE2DD Q33288884-BF46A776-BA17-4C41-96C7-679AB919ED80 Q33358519-0F9488FD-2145-4337-9FDC-72A65AAA08A2 Q33813264-13698C82-4386-4466-91C1-56BA72C5A0E2 Q34315836-E656AE0D-C82E-4F79-BB38-C685F7500787 Q34523972-9FB6D09A-3BDE-41A0-B38D-41BC09B49E25 Q34564181-A66A1BEF-012D-40DE-947C-B731938EA20B Q34623350-7D1B209D-9E10-49AB-A4E0-2861CCA760C9 Q34626443-F0CC6FF6-64D2-4AF6-ADEB-48FBFCC93CB5 Q34661499-8B8C1048-378C-42D6-8A0F-D9FCBB101562 Q35313130-78893A2B-1B14-41F8-A400-54AC68F658FD Q35530406-DFF621E5-897D-4979-B4D9-6B7E73438437 Q35549628-41B4781C-AB74-459F-BF76-64EA7D35DE14 Q35834883-973A8D29-9C41-4BB5-9E1C-110FFA9AF0E1 Q35974121-0367840F-EC3C-4811-B67B-7D350E98174C Q36118736-D3252706-C363-4B24-A2A5-85078C128F13 Q36143815-5C9DC082-23A2-4837-B4AF-2E2DDFDBDFA1 Q36466996-ACC7DDEB-E58B-4EB3-8CF8-45C68144D273 Q36852489-302415AA-0BA1-4D16-9877-8A1F54D1B059 Q36893286-ABBF40FC-66C1-4D5B-BA45-E9E258AA0AED Q37079080-2D7E6D37-88A6-470D-9B1D-15AC2631AC2A Q37129646-649DF14E-B4E6-4016-B84C-B12D6A93F6FD Q37281394-0B38BC02-41FC-42FC-AC29-4B35EF9A2D72 Q37290165-A6F9FCAA-92CB-45FB-B1D0-800595C22BEC Q37307741-D969295B-AAF4-4803-B3C1-43005CFFE0C1 Q37682840-AA5AAC9B-4A9E-4097-8584-9D7F5A01F928 Q37915662-19FD8937-166B-42DF-9E68-4E8E7772E403 Q38033144-2AFF960A-635A-4767-B25A-E07D28D43433 Q38190416-00F77C9F-5981-4EA6-A25C-1DC82F629143 Q38756380-C31E53A1-C943-4B16-BB3E-E1D4BE1CB07F Q38850666-D9483563-38D9-4DF2-AC46-9A35E4EDEED9 Q41657238-E7D25E69-4746-4D95-AA96-7226937A93D0 Q42114810-A02D0FBB-27F7-41CC-8DC1-6726029527A7 Q46195221-B68CB778-F861-4ACF-81A7-0DCDEBE9806F Q46756223-D46944E7-F87C-4F7D-9C88-C2926E2682D2 Q47411862-D6F0D35E-A190-418C-98FD-C7BF74A72E03

P2860

Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study

http://www.wikidata.org/entity/Q34944648

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Prevalence of diabetes, metabo ...... lness: a cross-sectional study

@ast

Prevalence of diabetes, metabo ...... lness: a cross-sectional study

@en

Prevalence of diabetes, metabo ...... lness: a cross-sectional study

@nl

type

label

Prevalence of diabetes, metabo ...... lness: a cross-sectional study

@ast

Prevalence of diabetes, metabo ...... lness: a cross-sectional study

@en

Prevalence of diabetes, metabo ...... lness: a cross-sectional study

@nl

prefLabel

Prevalence of diabetes, metabo ...... lness: a cross-sectional study

@ast

Prevalence of diabetes, metabo ...... lness: a cross-sectional study

@en

Prevalence of diabetes, metabo ...... lness: a cross-sectional study

@nl

P1433

Q34944648-12899145-0DBA-4738-AF45-D344267E5999

P1476

Q34944648-40488368-1DD7-475A-A15B-E6D25AB71A68

P2093

Q34944648-00271468-8603-4DEC-B630-E65B5E46B3D0

Q34944648-366477EA-4CF3-4FAC-AB34-D7F32EEB20B1

Q34944648-7BD32125-F69C-4AA0-AFD3-FD16752D304A

Q34944648-BAC3E62B-FE6B-4971-878B-9A0068971D53

Q34944648-C18AFFBD-0D27-474E-9877-C9A1A085E8C9

Q34944648-CC3EA472-DC3F-4875-BC3C-051C8189ACFD

Q34944648-DA2226E0-7FBB-4175-8544-03DAB7B2179C

P2860

Q34944648-047615E6-A4D1-478E-9C0E-6E56C4793C71

Q34944648-0E02F935-8DB7-4963-837D-CC456DCA19DE

Q34944648-0EBBAD65-C4FE-40CD-99B1-66008EF735B2

Q34944648-0F62C06B-8F6F-4C77-95C8-ACEAD5CABD17

Q34944648-11657079-49AB-478F-81AC-5E78228241E8

Q34944648-16876F8B-DF17-4205-B942-80DE007AA995

Q34944648-19917FB4-27B6-4FC0-BDC3-5422941E1FD5

Q34944648-256A9ADF-3FFE-4270-BDB0-1C5E9BB62CA9

Q34944648-32E0DDF4-D254-4EBE-AB93-AA8B4517E6CE

Q34944648-337A8EF8-562A-4F12-9BE4-044C436C0691

P2888

Q34944648-33F51CA1-F470-4C81-AA2F-4A2F5A770BB5

P304

Q34944648-F2E88F7B-B13D-4244-9BEB-2B09C14E1E17

P31

Q34944648-13F57798-A725-4154-AD62-9E5C443487FF

P356

Q34944648-C4BAC750-8AAA-4D16-BE3C-D5B73EFA2ED5

P478

Q34944648-525B4AF8-72CE-4AB0-BC56-5CF49F39CEB0

P577

Q34944648-FD38D918-A4A1-4FC6-AB72-CE7EE5733B64

P5875

Q34944648-8CE16DC1-7C14-4306-B73E-F8F5401F36BE

P6179

Q34944648-C103D701-25DB-4CC8-B4D3-42BF5733327A

P698

Q34944648-612097C0-3796-4D2F-818A-0454296DBECC

P921

Q34944648-0FCD16AA-22B7-4391-B845-1F69B73CB4EA

Q34944648-C0015268-EF33-4C1B-9F68-8C421C1DF3BE

P932

Q34944648-BBA256C4-DDBF-4AA5-AC47-CFA5FDCC8494

P356

P1433

Clinical Practice and Epidemiology in Mental Health

P1476

Prevalence of diabetes, metabo ...... lness: a cross-sectional study

@en

P2093

A Scheen

http://www.w3.org/2001/XMLSchema#string

D Van Eyck

http://www.w3.org/2001/XMLSchema#string

J Peuskens

http://www.w3.org/2001/XMLSchema#string

L Hanssens

http://www.w3.org/2001/XMLSchema#string

M De Hert

http://www.w3.org/2001/XMLSchema#string

M Wampers

http://www.w3.org/2001/XMLSchema#string

R van Winkel

http://www.w3.org/2001/XMLSchema#string

P2860

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

Causes of the excess mortality of schizophrenia.

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Report of the expert committee on the diagnosis and classification of diabetes mellitus.

Antipsychotic-induced weight gain: a review of the literature.

Consensus development conference on antipsychotic drugs and obesity and diabetes.

Physical health monitoring of patients with schizophrenia.

Hyperglycemia and antipsychotic medications.

P2888

P304

14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1745-0179-2-14

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2006-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6980340

http://www.w3.org/2001/XMLSchema#string

P6179

1045387912

http://www.w3.org/2001/XMLSchema#string

P698

16803620

http://www.w3.org/2001/XMLSchema#string

P921

metabolic syndrome

P932

1533826

http://www.w3.org/2001/XMLSchema#string